XML 38 R27.htm IDEA: XBRL DOCUMENT v3.22.2.2
Acquisitions, Divestitures and Strategic Investments (Tables)
 9 Months Ended
Sep. 30, 2022
Business Acquisition [Line Items]  
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]
Changes in the fair value of our contingent consideration liability during the first nine months of 2022 were as follows:

(in millions)
Balance as of December 31, 2021$486 
Contingent consideration net expense (benefit)68 
Contingent consideration payments(371)
Balance as of September 30, 2022$182 
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]
The recurring Level 3 fair value measurements of our contingent consideration liability that we expect to be required to settle include the following significant unobservable inputs:
Contingent Consideration LiabilityFair Value as of September 30, 2022Valuation TechniqueUnobservable InputRange
Weighted Average(1)
R&D, Regulatory and Commercialization-based Milestones$48 millionDiscounted Cash FlowDiscount Rate1%-2%1%
Probability of Payment70%-80%74%
Projected Year of Payment2023-20252024
Revenue-based Payments$134 millionDiscounted Cash FlowDiscount Rate6%-14%7%
Probability of Payment100%100%
Projected Year of Payment2023-20242023
(1)    Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.
Investment [Table Text Block]
The aggregate carrying amount of our strategic investments was comprised of the following:

As of
(in millions)September 30, 2022December 31, 2021
Equity method investments$207 $259 
Measurement alternative investments(1)
171 142 
Publicly-held securities(2)
3 10 
Notes receivable8 — 
$389 $412 
(1)    Measurement alternative investments are privately-held equity securities without readily determinable fair values that are measured at cost less impairment, if any, adjusted to fair value for any observable price changes in orderly transactions for the identical or a similar investment of the same issuer, recognized in Other, net within our accompanying unaudited consolidated statements of operations.
(2)    Publicly-held securities are measured at fair value with changes in fair value recognized in Other, net within our accompanying unaudited consolidated statements of operations.
Baylis Medical  
Business Acquisition [Line Items]  
Schedule of Business Acquisitions, by Acquisition [Table Text Block] The final determination of the fair value of certain assets and liabilities will be completed within the measurement period in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 805, Business Combinations (FASB ASC Topic 805).
(in millions)
Payment for acquisition, net of cash acquired$1,463 
$1,463 
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]
The preliminary purchase price allocation was comprised of the following components:
(in millions)
Goodwill$988 
Amortizable intangible assets657 
Other assets acquired112 
Liabilities assumed(287)
Net deferred tax liabilities(7)
$1,463 
Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]
We allocated a portion of the preliminary purchase price to the specific intangible asset categories as follows:
Amount Assigned
(in millions)
Weighted Average Amortization Period
(in years)
Risk-Adjusted Discount
Rates used in Purchase Price Allocation
Amortizable intangible assets:
Technology-related$622 1111%
Other intangible assets36 1111%
$657 
2021 Acquisitions  
Business Acquisition [Line Items]  
Schedule of Business Acquisitions, by Acquisition [Table Text Block] The final purchase prices were comprised of the following components:
(in millions)PreventiceLumenisFarapulseTotal
Payment for acquisition, net of cash acquired$706 $1,032 $268 $2,007 
Fair value of contingent consideration221 — 162 384 
Fair value of prior interest269 — 222 491 
$1,197 $1,032 $653 $2,882 
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]
(in millions)PreventiceLumenisFarapulseTotal
Goodwill$926 $534 $384 $1,843 
Amortizable intangible assets237 423 267 928 
Indefinite-lived intangible assets— 69 43 112 
Other assets acquired65 297 9 372 
Liabilities assumed(32)(282)(10)(323)
Net deferred tax liabilities— (9)(40)(49)
$1,197 $1,032 $653 $2,882 
Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]
We allocated a portion of the purchase price to the specific intangible asset categories as follows:

Amount Assigned
(in millions)
Weighted Average Amortization Period
(in years)
Risk-Adjusted Discount
Rates used in Purchase Price Allocation
Preventice:
Amortizable intangible assets:
Technology-related$215 910%
Other intangible assets22 810%
$237 
Lumenis:
Amortizable intangible assets:
Technology-related$388 1211%
Other intangible assets35 1111%
Indefinite-lived intangible assets:
In-process research and development (IPR&D)69 N/A12%
$492 
Farapulse:
Amortizable intangible assets:
Technology-related$267 1216%
Indefinite-lived intangible assets:
In-process research and development (IPR&D)43 N/A17%
$310